Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

News

Recent News

New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer  -  4/2/2020
Breakthrough blood test detects relapse earlier and helps patients avoid unnecessary clinic visits with GI Expanded Access Program SAN CARLOS, Calif. , April 2, 2020 /PRNewswire/ -- A new, peer-reviewed case study published in JCO Precision Oncology 1 demonstrates the unique ability of Signatera More »
Natera Provides Remote Access to Tests Without Requiring Live Office Visits  -  3/19/2020
Enabling continuity of care while allowing patients to stay home SAN CARLOS, Calif. , March 19, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities More »
Natera to Showcase Leadership in Cell-Free DNA at CEoT Conference  -  3/4/2020
SAN CARLOS, Calif. , March 4, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will be participating in the Cutting Edge of Transplantation (CEoT) conference taking place March 5-7, 2020 in Phoenix, Arizona . More »
Natera to Participate in Upcoming Investor Conferences  -  3/3/2020
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast live presentations at the Cowen and Company 40 th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 8:20 More »
Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™  -  3/3/2020
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75 . More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Date
Title
Wednesday, 03/11/20 at 12:20 PM PDT

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.